Atea Q1 net loss $45.4M ($0.57/shr); HCV Phase 3 topline mid-2026

Atea Pharmaceuticals, Inc.

2026-Q1 EPS reported -$0.57 vs consensus -$0.60 ▲ beat (+5.3%)

Net loss $45.4M vs $34.3M YoY; R&D spend rose to $41.1M on HCV Phase 3 and HEV preclinical.
Cash, equivalents & marketable securities $256.0M at March 31, 2026, down from $301.8M at Dec 2025.
C-BEYOND HCV Phase 3 (North America) enrollment completed; topline results expected mid-2026.
C-FORWARD HCV Phase 3 (ex-North America) enrollment on track to complete mid-2026; topline around year-end 2026.
HEV program: AT-587 selected as lead; in vitro data 30-150x more potent than sofosbuvir/ribavirin; Phase 1 initiation planned mid-2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Atea Pharmaceuticals, Inc. reported financial results for for the first quarter ended March 31, 2026.

Period: for the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 12, 2026, Atea Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Atea Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-219507

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.